Drug Trial Radar · NCT06182124
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,710
Actual
Start
Dec 20, 2023
Primary completion
May 12, 2026
Study completion May 12, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after participants have completed Stage 1, and a pneumococcal vaccine candidate has been decided. Stage 2 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or 20vPnC (Prevnar 20). The vaccines will be given as a single shot into the upper arm muscle. Stage 3 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or a licensed pneumococcal comparator vaccine. The vaccines will be given as a single shot into the upper arm muscle. Stage 4 is seeking participants who are adults 50 years of age and older. The participants will receive either one of three pneumococcal vaccine candidates or one of two licensed pneumococcal comparator vaccines. The vaccines will be given as a single shot into the upper arm muscle. Participants will take part in this study for about 6 months for Stage 1, Stage 3, and Stage 4 and 12 months for Stage 2. During this time participants will have from 2 to 4 clinic visits and 1 phone visit. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these clinic visits.
Conditions
- Pneumococcal Disease
Interventions
Multivalent Pneumococcal Vaccine - Formulation 1Biological
Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).
Multivalent Pneumococcal Vaccine - Formulation 2Biological
Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).
20-valent pneumococcal conjugate vaccine (20vPnC)Biological
20-valent pneumococcal conjugate vaccine (20vPnC)
Licensed pneumococcal comparator vaccineBiological
A licensed pneumococcal comparator vaccine
Multivalent Pneumococcal Vaccine - Formulation 3Biological
Multivalent pneumococcal conjugate vaccine
Multivalent Pneumococcal Vaccine - Formulation 4Biological
Multivalent pneumococcal conjugate vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting prespecified local reactions within 7 days after vaccinationTime frame: 7 days
- Percentage of participants reporting prespecified systemic events within 7 days after vaccinationTime frame: 7 days
- Percentage of participants reporting Adverse Events (AEs) within 1 month after vaccinationTime frame: 1 month
- Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccinationTime frame: 6 months
- Phase 2 (Stage 2) Only: Percentage of participants reporting related Serious Adverse Events (SAEs) through 12 months after vaccinationTime frame: 12 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Alliance for Multispecialty Research, LLC
Doral, Florida
Indago Research & Health Center, Inc
Miami Lakes, Florida
Clinical Research Atlanta
Stockbridge, Georgia
Optimal Research
Peoria, Illinois
Alliance for Multispecialty Research, LLC
New Orleans, Louisiana
Headlands Research - Detroit
Southfield, Michigan
Rochester Clinical Research, LLC
Rochester, New York
Accellacare - Wilmington
Wilmington, North Carolina
AMR Clinical
Knoxville, Tennessee
AMR Clinical
Knoxville, Tennessee
Headlands Horizons LLC
Brownsville, Texas
DM Clinical Research- Cyfair
Houston, Texas
Clinical Trials of Texas, LLC dba Flourish Research
San Antonio, Texas
IMA Clinical Research San Antonio
San Antonio, Texas
Dynamed Clinical Research, LP d/b/a DM Clinical Research
Sugar Land, Texas
Dynamed Clinical Research, LP d/b/a DM Clinical Research
Tomball, Texas
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.